First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors (NCT05875168)

🧪 Interventions in This Study

• DS-3939a (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (36 Sites)

Showing the first 25 of 36 sites.

• Florida Cancer Specialists — Sarasota, Florida
• University of Kansas Medical Center — Westwood, Kansas
• Oregon Health & Science University — Portland, Oregon
• Rhode Island Hospital — Providence, Rhode Island
• University of Texas M.D. Anderson Cancer Center — Houston, Texas
• Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
• The Medical College of Wisconsin, INC — Milwaukee, Wisconsin
• UZ Leuven — Leuven,
• McGill University Health Center — Montreal,
• Princess Margaret Cancer Center — Toronto,
• Beijing Cancer Hospital — Beijing,
• Shandong Cancer Hospital — Jinan,
• The Second Peoples Hospital of Neijiang — Neijiang,
• Shanghai East Hospital — Shanghai,
• Centre Léon Bérard — Lyon,
• Assistance Publique- de Marseille — Marseille,
• Chu Strasbourg — Strasbourg,
• Institut Claudius Regaud — Toulouse,
• Institut Gustave Roussy — Villejuif,
• National Cancer Center Hospital — Chūōku,
• Kansai Medical University Hospital — Hirakata-shi,
• National Cancer Center Hospital East — Kashiwa,
• Cancer Institute Hospital of Jfcr — Kōtoku,
• Osaka International Cancer Institute — Osaka,
• Kindai University Hospital — Ōsaka-sayama,

📞 Contact the Study Coordinator

Phone: (908) 992-6400

Email: CTRinfo@dsi.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumor

• Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
• A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
• QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
• A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
• First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
• A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas

Explore by condition: All Advanced Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.